Navigation Links
Actavis and Medicines360 Announce Partnership to Advance Women's Access to Affordable IUDs
Date:6/11/2013

SAN FRANCISCO and PARSIPPANY, N.J., June 11, 2013 /PRNewswire/ -- Medicines360, a non-profit pharmaceutical company, and Actavis, Inc., a leading global specialty pharmaceutical company, today announced a historic partnership to support Medicines360's mission to reduce cost as a barrier to accessing women's birth control.  The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics.  As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device (IUD). Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women.  LNG20, originally developed by Uteron Pharma S.P.R.L. in Belgium, is designed to initially deliver 20 mcg of levonorgestrel per day for the indication of long term contraception, and is currently in Phase III clinical trials in the United States.  Pending U.S. Food and Drug Administration (FDA) approval, the LNG20 IUD could be launched in the U.S. as early as 2014. 

"Addressing unmet needs of underserved women is the reason Medicines360 exists," said Victoria Hale, PhD, Medicines360 Founder & CEO. "The belief that companies have to choose between serving the public sector and making money is a fallacy but we're setting out to demonstrate the ways in which this is possible. It doesn't have to be a money-losing proposition or perpetually financed through philanthropy. IUDs in general have been shown to be a very effective contraceptive, but have been too expensive for most women.  My motivation is to provide access to effective birth control options regardless of a person's income.  Actavis shares our vision of a world in which a woman's access to birth control is
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
2. Actavis, Inc. to Present at the Goldman Sachs 34th Annual Global Healthcare Conference 2013
3. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
4. Actavis NDA for Progestin-Only Patch Accepted for Filing by FDA
5. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
6. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
7. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
8. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
9. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
10. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
11. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... remains unknown. Scientists believe people may have gotten the virus from ... want to quarantine the pets as well as the people," suggested ... of Texas Medical Branch in Galveston. "If it's been shown that ... much of a leap of faith that it will transmit to ...
... viral cold are common in preschoolers. These attacks are ... school age. //The current recommendation is that parents administer ... But whether or not the steroids are effective is ... steroids was no more effective than placebo in reducing ...
... cardiac death is termed sudden arrhythmic death syndrome or ... United States.// Most of these sudden deaths involve middle-aged ... in young people are rare, experts say they do ... the families. ,Previous research indicates about 4 ...
... with type 2 diabetes and now research shows this diagnosis ... heart attack and stroke. //Specifically, the research shows younger adults ... suffer a heart attack and 30-times more likely to suffer ... that huge numbers of people are going to get heart ...
... An oral drug given after a standard six-month treatment ... to new research.// ,Venous thromboembolism (VTE) affects approximately ... thrombosis (blood clots common in the thigh and back) ... Despite progress in diagnosis and treatment, VTE is still ...
... may soon be fighting a losing battle. Scientists from ... stopped the tuberculosis pathogen's ability to operate from the ... system in a cell called a macrophage. ,The ... triggered by a host protein called interferon-gamma that disarms ...
Cached Medicine News:Health News:Some pets found to be SARS carriers 2Health News:Extended Therapy for Blood Clots 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: